Clinical Milestones. Celgene shall make the following clinical milestone payments to Jounce that are set forth below upon the first achievement by or on behalf of Celgene, its Affiliates or Sublicensees of the Clinical Milestone Events set forth below with respect to the first Co-Co Product that achieves such event. For clarity, each milestone set forth below shall be due and payable one time only (regardless of the number of Co-Co Products to achieve any such Clinical Milestone Event). Clinical Milestone Event (For the first Co-Co Product that achieves such event) Milestone Payments (in $ millions) [***] [***] [***] [***] [***] [***]
Clinical Milestones. Event The First Profile to Achieve the Event The Second Profile to Achieve the Event Start of Phase I Study (first patient, first dosing) $[**] regardless of indication $[**] regardless of indication Start of Phase II Study (first patient, first dosing) $[**] for the first Major Indication $[**] for the first Major Indication Start of Phase II Study (first patient, first dosing) $[**] for the first Minor Indication $[**] for the first Minor Indication Start of Phase III Study (first patient, first dosing) $[**] for the first Major Indication $[**] for the first Major Indication Start of Phase III Study (first patient, first dosing) $[**] for the first Minor Indication $[**] for the first Minor Indication The Phase I Study milestone set forth in this Section 7.4.2 shall be payable only once for each Profile. All other milestones set forth in this Section 7.4.2 at each milestone event shall be payable only once for each Profile and only once for each Major Indication and Minor Indication, irrespective of Profile. For the avoidance of doubt: (a) in the event that a Phase II Study is commenced in [**] (a Major Indication) in two Profiles, only one (1) milestone shall be due; (b) in the event that a Phase II Study is commenced in [**] and in [**] (both of which are Major Indications) in the same Profile, only one (1) milestone shall be due; (c) in the event that a Phase II Study is commenced in [**] in the Bcl-2 Selective Profile and a Phase II Study is commenced in [**] in the Dual Profile, a Major Indication milestone for each shall be due; (d) in the event that a Phase II Study is commenced in [**] in the Bcl-2 Selective Profile (at which point the first Major Indication milestone is paid) and then a Phase II Study is commenced in [**] in the Bcl-2 Selective Profile (at which point no Major Indication milestone is paid) and subsequently to these two trials, a Phase II Study is commenced in [**] in the Dual Profile, then a second Major Indication milestone shall be due; and (e) in the event that the first Profile to be Developed by Novartis achieves the Phase I Study milestone and achieves the Phase II Study and Phase III Study Milestones for both a Major Indication and a Minor Indication, a total of $[**] shall be payable hereunder. If an NDA is filed after the end of a Phase II Study for a Licensed Compound, then the Phase III Study milestone event shall be deemed achieved as of the date of such filing.
Clinical Milestones. Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
Clinical Milestones. In consideration for the rights granted to Roche under this Agreement, Roche shall make the following one-time, non-refundable, non-creditable milestone payments to Prothena (up to a total of $[*] per Licensed Product) within [*] after the achievement of the relevant milestone for each Licensed Product and receipt by Roche of an invoice for such amount from Prothena; [*]: Milestone Event Payment (i) [*] $15,000,000 (ii) [*] $[*] (iii) [*] $[*] (iv) [*] $[*] Notwithstanding the foregoing, [*]. The following summarizes the percentage of the payments set forth above that are due with respect to various types of Licensed Compounds: Type of Licensed Compound Percentage of milestone amount due to Prothena (based on the table immediately above), if such Licensed Compound [*] Percentage of milestone amount due to Prothena (based on the table immediately above), if such Licensed Compound [*] [*] [*]% [*]% [*] [*]% [*]% [*] [*]% [*]% [*] [*]% [*]% The Parties will coordinate to have separate invoices with respect to each milestone payment so that accounting can be allocated appropriately (based on [*] or as otherwise mutually agreed by the JFT) to Roche Nutley and Prothena US for the portion of such milestone payment related to the United States and to Roche Basel and Prothena Ireland for the balance of such milestone payment.
Clinical Milestones. Hyseq will pay to Aurora the following non-creditable, non-refundable milestone payments for the first, and only the first, Hyseq Product within [***] following achievement of each of the following milestone events: Milestone Payment --------- ------- [***]
Clinical Milestones. First site initiation of protocol for Sarcoma Cohort 2 of the Phase I/IIa Sarcoma cancer study (“Sarcoma Cohort 2”) 2.5 First site initiation of protocol for Sarcoma Cohort 3 of the Phase I/IIa Sarcoma study (“Sarcoma Cohort 3”) 2.5 First site initiation of protocol for the Phase I/IIa NSCLC study included in the Initial Development Plan (“NSCLC Study”) 2.5 *** 2.5 *** *** *** *** *** *** *** *** Initiation of companion diagnostic development program as defined in the Initial Development Plan 2.0 *** ***
Clinical Milestones. Within forty-five (45) days following the first occurrence of each of the events set forth below with respect to each Product, as applicable, LG Chem shall pay to Elitra the milestone payment set forth below: ------------------------------------------------ --------------------------- MILESTONE EVENT MILESTONE PAYMENT ------------------------------------------------ --------------------------- [...***...] of Product $[...***...] ------------------------------------------------ --------------------------- [...***...] of Product $[...***...] ------------------------------------------------ --------------------------- [...***...]of Product $[...***...] ------------------------------------------------ --------------------------- [...***...] for Product in [...***...] $[...***...] ------------------------------------------------ --------------------------- [...***...] of Product in [...***...] $[...***...] ------------------------------------------------ --------------------------- Each of the foregoing milestone payments shall be payable on a Program Compound-by-Program Compound basis; PROVIDED, HOWEVER, that if (i) a Product is abandoned during development after one or more of the milestone payments under this Section 7.3(b) has been made and (ii) a Product comprising or containing another Program Compound previously designated by the JDC as a back-up compound for such abandoned Product is developed for the same indication as the abandoned Product to replace such abandoned Product, then only those milestone payments under this Section 7.3(b) that were not previously made with respect to such abandoned Product shall be payable with respect to the Product comprising or containing such back-up Program Compound. All payments made to Elitra pursuant to this Section 7.3 are non-refundable and may not be credited against any other payments payable by LG Chem to Elitra under this Agreement.
Clinical Milestones a. With respect to a first Product, Amgen shall pay to GENE the following one-time, non-refundable, non-creditable payments via wire transfer to an account designated by GENE within ***** days following the achievement by Amgen, its Affiliates or sublicensees, of each of the clinical milestones set forth below: MILESTONE EVENT MILESTONE PAYMENT ***** US$***** ***** US$***** ***** US$***** ***** US$***** ***** US$***** Total US$
Clinical Milestones. For each Hyseq Target, Aurora will pay to Hyseq the following non-creditable, non-refundable milestone payments for the first, and only the first, Aurora Product to achieve such milestone. This payment will be made within [***] following achievement of each of the following milestone events: CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Milestone Payment --------- ------- [***] [***]
Clinical Milestones. 10.1 On a Product-by-Product basis, within [*] following the first achievement or occurrence, by the performance of Amgen or a Sublicensee of Amgen, of each of the following clinical milestone events with a Product ("Clinical Milestone Event(s)"), Amgen shall pay to Immunomedics the corresponding one-time clinical milestone payments set forth hereinbelow for each such Product ("Clinical Milestone Payment(s)"):
